Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Standard

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). / Уразгильдеева, Сорейя Асафовна ; Гуревич, Виктор Савельевич.

In: Atherosclerosis, Vol. 277, 10.10.2018, p. 234-255.

Research output: Contribution to journal › Article › peer-review

BibTeX

@article{0fbb14672d224165adb2c37f8411e53d,

title = "Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)",

abstract = "Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.",

keywords = "FHSC, Familial hypercholesterolaemia, Primary dyslipidaemia",

author = "Уразгильдеева, {Сорейя Асафовна} and Гуревич, {Виктор Савельевич}",

note = "Funding Information: The EAS FHSC project has received support from a Pfizer Independent Grant for Learning & Change 2014 (No: 16157823 ) and from investigator-initiated unrestricted research grants to the European Atherosclerosis Society from Amgen , MSD , and Sanofi-Aventis . Acknowledgments for/from specific initiatives and investigators are shown in the Supplemental Material . Appendix A Funding Information: National Lead Investigators for each country are identified as “NLI”. FHSC COORDINATING CENTRE : Asif Akram i , Josip Car i , Martina De Marco i , Kausik K. Ray i , Christophe A.T. Stevens i , Antonio J. Vallejo-Vaz i ; (i) Imperial College London, United Kingdom . ARGENTINA: Pablo Corral i (NLI), Laura Schreier ii ; (i) FASTA University, School of Medicine, Pharmacology Dept., Mar del Plata; (ii), University of Buenos Aires, Dept. of Clinical Biochemistry, Laboratory of Lipids and Atherosclerosis, INFIBIOC-UBA, Buenos Aires . AUSTRALIA: Gerald F. Watts i-iii (NLI), Jing Pang i ; (i) School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth; (ii) Lipid Disorders Clinic, Dept. of Cardiology, Royal Perth Hospital; (iii) FH Australasia Network (FHAN) . AUSTRIA: Christoph J. Binder i (NLI), Hans Dieplinger ii , Gabriele Hanauer-Mader iii ; (i) Dept. of Laboratory Medicine, Medical University of Vienna; (ii) Division of Genetic Epidemiology, Dept. of Medical Genetics, Clinical and Molecular Pharmacology, Innsbruck Medical University; (iii) Project Coordinator FH Registry/Austrian Atherosclerosis Society . BELGIUM: Olivier Descamps i (NLI), Johan Desutter ii , Michel Langlois iii , Ann Mertens iv , Ernst Rietzschel ii , Caroline Wallemacq v ; (i) Centres Hospitaliers Jolimont, Haine Saint-Paul; (ii) UZ Gent; (iii) AZ Brugge; (iv) UZ Leuven; (v) CHU Li{\`e}ge . BOSNIA AND HERZEGOVINA: Belma Pojskic i (NLI), Dzenana Isakovic i , Amra M. Dzankovic ii , Jasna Obralija iii , Lamija Pojskic i , Ibrahim Sisic i , Ena Stimjanin i , Vildana A. Torlak i ; (i) Cantonal Hospital Zenica; (ii) Private Internal Medicine Practice, Sarajevo; (iii) PI Health Center of Kakanj . BRAZIL: Raul D. Santos i,ii (NLI), Cinthia E. Jannes i , Jose E. Krieger i , Alexandre C. Pereira i ; (i) Heart Institute (InCor) University of Sao Paulo, Medical School Hospital; (ii) Hospital Israelita Albert Einstein, Sao Paulo . BULGARIA: Arman Postadzhiyan (NLI), Medical University of Sofia, President, Bulgarian Society of Cardiology . CANADA: Jacques Genest i (NLI), Isabelle Ruel i,ii ; (i) Research Institute of the McGill University Health Center, Montreal, Quebec; (ii) FH Canada Registry Coordinator . CHILE: Rodrigo Alonso i (NLI), Sylvia Asenjo ii , Ada Cuevas i ; (i) Cl{\'i}nica Las Condes, Santiago de Chile; (ii) Universidad de Concepci{\'o}n . CHINA: Jie Lin i (NLI), Lixin Jiang ii (NLI); (i) Beijing Institute of Heart, Lung and Blood Vessel Diseases; (ii) National Clinical Research Centre of Cardiovascular Diseases, Fuwai Hospital, National Centre for Cardiovascular Diseases, Beijing . CROATIA: {\v Z}eljko Reiner i (NLI), Ivan Pe{\'c}in i ; (i) University of Zagreb, Zagreb School of Medicine, Dept. of Internal Medicine, Division of Metabolic Diseases, University Hospital Center Zagreb . CYPRUS: Phivos Symeonides i (NLI), George Miltiadous ii , Andrie G. Panayiotou ii ; (i) Hippocrateon Private Hospital, Nicosia; (ii) Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol . CZECH REPUBLIC: Tomas Freiberger i,ii (NLI), Michal Vrablik iii ; (i) Centre for Cardiovascular Surgery and Transplantation, Brno; (ii) Central European Institute of Technology, Masaryk University, Brno; (iii) General University Hospital and First Faculty of Medicine, Charles University, Prague . DENMARK: B{\o}rge G. Nordestgaard i,ii (NLI), Anne Tybj{\ae}rg-Hansen i-iii (NLI), Marianne Benn ii,iii ; (i) Dept. Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital; (ii) Faculty of Health and Medical Sciences, University of Copenhagen; (iii) Dept. Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital . EGYPT: Ashraf Reda (NLI), Menofia University, President of the Egyptian Association of Vernacular Biology and Atherosclerosis (EAVA) . ESTONIA: Margus Viigimaa i (NLI), Silver Heinsar ii ; (i) Centre for Cardiovascular Medicine, North Estonia Medical Centre, Tallinn University of Technology; (ii) North Estonia Medical Centre, Tallinn University of Technology . FINLAND: Elisabeth Wid{\'e}n (NLI), Institute for Molecular Medicine Finland FIMM, University of Helsinki . FRANCE: Eric Bruckert i (NLI), S. B{\'e}liard ii ; (i) Dept. of Endocrinology, Institut E3M et IHU cardiom{\'e}tabolique, H{\^o}pital Piti{\'e} Salp{\^e}tri{\`e}re, Paris; (ii) Dept. of Endocrinology, APHM, Aix Marseille Univ, INSERM, INRA, C2VN, Marseille . GERMANY: Ulrich Laufs i (NLI), Winfried M{\"a}rz ii-v (NLI), Heribert Schunkert vi (NLI), Ioanna Gouni-Berthold vii , Wibke Hengstenberg viii , Ulrich Julius ix , Ursula Kassner x , Gerald Klose xi , Christel K{\"o}nig xii , Wolfgang K{\"o}nig viii , Britta Otte xiii , Klaus Parhofer xiv , Ulrike Schatz ix , Nina Schmidt iv , Elisabeth Steinhagen-Thiessen x , Anja Vogt xiv ; (i) Klinik und Poliklinikf{\"u}r Kardiologie, Universit{\"a}ts klinikum Leipzig; (ii) Medizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakult{\"a}t Mannheim der Universit{\"a}t Heidelberg, Mannheim; (iii) Synlab Akademie, Synlab Holding Deutschland GmbH, Mannheim und Augsburg; (iv) D-A-CH-Gesellschaft Pr{\"a}vention von Herz-Kreislauf-Erkrankungen e.V., Hamburg; (v) KlinischesInstitutf{\"u}r Medizinische und Chemische Labordiagnostik, Medizinische Universit{\"a}t Graz, Graz, Austria; (vi) Deutsches Herzzentrum M{\"u}nchen, Technische Universit{\"a}t M{\"u}nchen, Deutsches Zentrumf{\"u}r Herz-und Kreislauferkrankungen (DZHK), Munich Heart Alliance; (vii) Center for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne; (viii) Deutsches Herzzentrum, Munich; (ix) Dept. of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universit{\"a}t Dresden; (x) Center for Internal Medicine with Gastroenterology and Nephrology, Lipid Clinic, Charit{\'e} Berlin; (xi) Joint Practice for Internal Medicine, Gastroenterology and Cardiology Beckenbauer & Maierhof, Bremen; (xii) Clinic of Internal Medicine, Lipid Clinic, Klinikum Links der Weser, Bremen; (xiii) Medical Clinic D, Lipid Clinic, University Hospital M{\"u}nster; (xiv) Medical Clinic and Policlinic IV, Ludwig-Maximilian University, Munich . GREECE: Evangelos Liberopoulos i (NLI), Alexandros D. Tselepis ii (NLI), Christina Antza iii , Vasilios Athyros iii , Eleni Bilianou iv , Amalia Boufidou v , George Chrousos vi , Moses Elisaf i , Anastasia Garoufi vii , Niki Katsiki viii , Genovefa Kolovou ix , Vasilios Kotsis iii , Loukianos Rallidis x , Christos Rizos i , Emmanouel Skalidis xi , Ioannis Skoumas xii , Kostantinos Tziomalos xiii ; (i) Faculty of Medicine, University of Ioannina; (ii) Atherothrombosis Research Centre, University of Ioannina; (iii) Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, Thessaloniki; (iv) Dept. of Cardiology, Tzaneio Hospital, Athens; (v) Dept. of Cardiology, AHEPA Hospital, Thessaloniki; (vi) First Dept. of Pediatrics, National and Kapodistrian University of Athens Medical School, St. Sophia Children Hospital, Athens; (vii) Second Dept. of Pediatrics, Medical School, National & Kapodistrian University of Athens, “P & A Kyriakou” Children's Hospital; (viii) Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, Hippokrateion Hospital, Thessaloniki; (ix) Dept. of Cardiology, Onassis Cardiac Surgery Centre, Athens; (x) Dept. of Cardiology, University of Athens Medical School, Attiko University Hospital, Athens; (xi) Dept. of Cardiology, University Hospital of Herakleion; (xii) Dept. of Cardiology, Hippokrateion Hospital, Athens; (xiii) First Propedeutic Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, AHEPA Hospital, Thessaloniki . HONG KONG: Brian Tomlinson (NLI), Dept. of Medicine and Therapeutics, The Chinese University of Hong Kong . HUNGARY: Gy{\"o}rgy Paragh (NLI), Dept. of Internal Medicine, University of Debrecen Faculty of Medicine, Debrecen . INDIA: Tester F. Ashavaid i (NLI), J.P.S. Shawney ii ; (i) P. D Hinduja National Hospital and Medical Research Centre, Mumbai; (ii) Sir Ganga Ram Hospital, Delhi . IRAN: Amirhossein Sahebkar i-iii (NLI), Mohammad R. Abbaszadegan iv , Majid Aminzadeh v , Sousan Hosseini iv , Moein Mobini vi , Rahim Vakili iv,vii , Hossein Zaeri viii ; (i) Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences; (ii) Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences; (iii) School of Pharmacy, Mashhad University of Medical Sciences; (iv) Medical Genetics Research Center, Mashhad University of Medical Sciences; (v) Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz; (vi) School of Medicine, Mashhad University of Medical Sciences; (vii) Dept. of Paediatric Endocrinology and Metabolism, Faculty of Medicine, Mashhad University of Medical Sciences; (viii) Neonatal and Children Health Research Centre, Golestan University of Medical Sciences, Gorgan . IRAQ: Mutaz Al-khnifsawi (NLI), Al-Qadisiyah University, Faculty of Medicine, Dept. of Internal Medicine, Diwaniya City . IRELAND: Vincent Maher i (NLI), Ruth Agar i , Gerard Boran ii , Nial Colwell iii , Vivion Crowley iv , Maeve Durkin v , Damian Griffin vi , Michael Kelly ii , Ana Rakovac-Tisdall iv ; (i) Advanced Lipid Management and Research (ALMAR) Centre, Dublin; (ii) Tallaght University Hospital, Dublin; (iii) South Tipperary General Hospital; (iv) St James Hospital, Dublin; (v) Bon Secours Hospital Cork; (vi) University Hospital Galway . ISRAEL: Ronen Durst i (NLI), Rafael Bitzur ii , Hofit Cohen ii , Osnat Eliav iii , Avishay Ellis iv , Dov Gavish v , Dror Harats ii , Yaacov Henkin vi , Hila Knobler vii , Leah Leavit iii , Eran Leitersdorf iii , Ardon Rubinstein viii , Daniel Schurr iii , Shoshi Shpitzen iii , Auryan Szalat iii ; (i) Cardiology Dept. and Center for Treatment and Prevention of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem; (ii) Bert W. Strassburger Lipid Center, the Chaim Sheba Medical Center, Tel Hashomer; (iii) Center for Research Prevention and Treatment of Atherosclerosis, Dept. of Medicine, Hadassah Hebrew University Medical Center, Jerusalem; (iv) Internal Medicine, Rabin Medical Center, Petah Tikva; (v) Dept. of Medicine, Wolfson Medical Center, Holon; (vi) Dept. of Cardiology, Soroka University Medical Center, Beer-Sheva; (vii) Diabetes and Metabolic Disease Unit, Kaplan Medical Center, Rehovot; (viii) Dept. of Metabolic Clinic, Tel Aviv Medical Center, Tel Aviv . ITALY: Alberico L. Catapano i,ii (NLI), Marcello Arca iii , Maurizio Averna iv , Stefano Bertolini v , Sebastiano Calandra vi , Patrizia Tarugi vii ; (i) Dept. of Pharmacological and Biomolecular Sciences, University of Milan, Milan; (ii) IRCCS MultiMedica, Sesto S. Giovanni, Milan; (iii) Dept. of Internal Medicine and Medical Specialties, Sapienza University, Rome; (iv) Biomedical Dept. of Internal Medicine and Specialistics (DIBIMIS), University of Palermo; (v) Dept. of Internal Medicine, University of Genoa; (vi) Dept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; (vii) Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena . JAPAN: Mariko Harada-Shiba i (NLI), Shizuya Yamashita ii (NLI); (i) National Cerebral and Cardiovascular Centre Research Institute, Suita, Osaka; (ii) Rinku General Medical Center and Osaka University Graduate School of Medicine, Osaka . KUWAIT: Ahmad Al-Sarraf (NLI), Laboratory Dept., Kuwait Cancer Control Center, Kuwait City . KYRGYZSTAN: Erkin Mirrakhimov (NLI), Kyrgyz State Medical Academy, National Centre of Cardiology and Internal Diseases, Biskek . LATVIA: Gustavs Latkovskis i (NLI), Andrejs Erglis i , Dainus Gilis ii , Georgijs Nesterovics iii , Vita Saripo iv , Arta Upena-Roze ii ; (i) Research Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga; (ii) University of Latvia, Pauls Stradins Clinical University Hospital, Riga; (iii) Faculty of Medicine, University of Latvia, Riga; (iv) Faculty of Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga . LEBANON: Marianne Abifadel i (NLI), Sandy Elbitar i , S{\'e}lim Jambart ii , Petra El Khoury i ; (i) Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, P{\^o}le Technologie-Sant{\'e}, Saint Joseph University, Beirut; (ii) Saint Joseph University of Beirut Faculty of Medicine and H{\^o}tel Dieu Hospital, Beirut . LITHUANIA: Zaneta Petrulioniene i-iii (NLI), Urte Gargalskaite i,iii , Sandra Kutkiene i-iii ; (i) Vilnius University, Faculty of Medicine; (ii) Vilnius University, Faculty of Medicine, Clinic of Cardiac and Vascular Diseases; (iii) Vilnius University hospital Santaros Klinikos . MALAYSIA: Hapizah M. Nawawi i (NLI), Alyaa Al-Khateeb, Chua Y. An, Zaliha Ismail, Sazzli Kasim, Khairul S. Ibrahim, Ahmad B.M. Radzi, Noor A. Kasim, Noor S.M. Nor, Anis S. Ramli, Suraya A. Razak, Suhaila Muid, Azhari Rosman, Abd R. Sanusi, Aimi Z. Razman, Sukma A. Nazli, Teh L. Kek; (i) Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), (ii) Faculty of Medicine Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, Selangor, (iii) National Heart Institute (IJN), Kuala Lumpur, (iv) The Malaysian Atherosclerosis Society (MSA) . MALTA: Myra Tilney i,ii (NLI), Conrad Azzopardi i,ii ; (i) Dept. of Medicine, Faculty of Medicine and Surgery, University of Malta; (ii) Lipid Clinic, Mater Dei Hospital . MEXICO: Carlos A. Aguilar Salinas i (NLI), N. Alejandra V{\'a}zquez-C{\'a}rdenas ii (NLI), Gabriela Gal{\'a}n i , MT Maga{\~n}a-Torres iii , Alexandro Martagon i , Roopa Mehta i ; (i) Instituto Nacional de Ciencias M{\'e}dicas y Nutrici{\'o}n, M{\'e}xico City; (ii) Facultad de Medicina, Universidad Aut{\'o}noma de Guadalajara, Guadalajara, M{\'e}xico; (iii) Centro de Investigaci{\'o}n Biom{\'e}dica de Occidente, Instituto Mexicano del Seguro Social . NETHERLANDS: G. Kees Hovingh i (NLI), John J.P. Kastelein i (NLI), M.E. Wittekoek ii ; (i) Dept. of Vascular Medicine, Academic Medical Center, Amsterdam; (ii) Director, LEEFH (Landelijk Expertisecentrum Erfelijksheidsonderzoek Familiaire Hart - En Vaatziekten) . NIGERIA: Wilson E. Sadoh i (NLI), Alphonsus R. Isara ii , Darlington E. Obaseki iii , Oluwatoyin A. Ohenhen iv ; (i) Cardiology unit, Dept. of Child Health, University of Benin Teaching Hospital, Benin City, Edo State; (ii) Dept. of Community Medicine, University of Benin Teaching Hospital, Benin City; (iii) Dept. of Pathology, University of Benin Teaching Hospital, Benin City; (iv) Dept. of Medicine, University of Benin Teaching Hospital, Benin City . NORWAY: Martin P. Bogsrud i,ii (NLI), Kirsten B. Holven ii,iii ; (i) Unit for Cardiac and Cardiovascular Genetics, Dept. of Medical Genetics, Oslo University Hospital; (ii) Norwegian National Advisory Unit on Familial Hypercholesterolemia, Dept. of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital; (iii) Dept. of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo . OMAN: Khalid Al-Rasadi (NLI), Sultan Qaboos University Hospital, Muscat . PHILIPPINES: Lourdes E. Santos (NLI); Cardinal Santos Medical Centre, University of the Philippines – Philippine General Hospital . POLAND: Maciej Banach i (NLI), Krzysztof Chlebus ii,iii , Marcin Grucha{\l}a ii,iii , Marlena Baranowska iii , Justyna Borowiec-Wolny iii , Natasza Gilis-Malinowska iii , Aleksandra Michalska-Grzonkowska iii , Marcin Pajkowski iii , Aleksandra Parczewska iii , Marzena Romanowska-Kocejko iii , Aneta Str{\'o}{\.z}yk iii , Marta {\.Z}arczy{\'n}ska-Buchowiecka ii,iv , Mariola Kleinschmidt v ; (i) Dept. of Hypertension, Medical University of Lodz; (ii) 1st Dept. of Cardiology, Medical University of Gdansk; (iii) Clinical Centre of Cardiology, University Clinical Centre in Gda{\'n}sk; (iv) Dept. of Heart Disease Diagnosis, University Clinical Centre in Gda{\'n}sk; (v) Dept. of Sales and Purchase of Medical Services, University Clinical Centre in Gda{\'n}sk. PORTUGAL: Mafalda Bourbon i,ii (NLI), Ana C. Alves i,ii , Ana M. Medeiros i,ii ; (i) Unidade I&D, Grupo de Investiga{\c c}{\~a}o Cardiovascular, Dept. de Promo{\c c}{\~a}o da Sa{\'u}de e Doen{\c c}as N{\~a}o Transmiss{\'i}veis, Instituto Nacional de Sa{\'u}de Doutor Ricardo Jorge, Lisboa; (ii) University of Lisboa, Faculty of Sciences, BioISI – Biosystems & Integrative Sciences Institute, Campo Grande, Lisboa . QATAR: Fahad A. AlKindi i (NLI), (i) Hamad Medical Corporation, Heart Hospital, Doha. ROMANIA: Dan Gaita (NLI); Universitatea de Medicina si Farmacie Victor Babes din Timisoara . RUSSIA: Marat Ezhov i (NLI), Andrey V. Susekov ii (NLI), Alexandra Ershova iii , Victoria Korneva iv , Tatiana Kuznetsova iv , Pavel Malyshev v , Alexey Meshkov iii , Tatiana Rozhkova v ; (i) National Cardiology Research Center of Ministry of Health of the Russian Federation; (ii) Faculty of Clinical Pharmacology and Therapeutics, Academy for Postgraduate Medical Education and Central Clinical Hospital, Academy of Medical Science, Moscow; (iii) Federal State Institution {"}National Research Center for Preventive Medicine{"} of the Ministry of Healthcare of the Russian Federation, Moscow; (iv) Petrozavodsk State University, Petrazavodsk; (v) National Research Center for Cardiology, Moscow . SAUDI ARABIA: Fahad Alnouri (NLI), Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre Riyadh, Riyadh . SERBIA: Katarina Lalic i (NLI), Natasa Rajkovic i , Ljiljana Popovic i , Sandra S. Lukac i , Ljubica Stosic i , Iva Rasulic i , Nebojsa M. Lalic i ; (i) Faculty of Medicine, University of Belgrade; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade . SINGAPORE: Tavintharan Subramaniam i-iii (NLI), Carolyn S.P. Lam iv (NLI), Terrance S.J. Chua v , Sharon P.L. Ting iii ; (i) Diabetes Centre, Admiralty Medical Centre; (ii) Division of Endocrinology, Khoo Teck Puat Hospital; (iii) Clinical Research Unit, Khoo Teck Puat Hospital; (iv) National Heart Centre Singapore, Duke-NUS Medical School; (v) National Heart Centre Singapore . SLOVAKIA: Branislav Vohnout i,ii (NLI), Katarina Raslova ii ; (i) Institute of Nutrition, FOZOS, Slovak Medical University, Bratislava; (ii) Coordination Center for Familial Hyperlipoproteinemias, Slovak Medical University, Bratislava . SLOVENIA: Zlatko Fras i,ii (NLI), Urh Groselj iii (NLI), Tadej Battelino iv , Matija Cevc i , Borut Jug i , Jernej Kovac iv , Katarina T. Podkrajsek iv , Ursa Sustar iv , Katja J. Trontelj i ; (i) University Medical Centre Ljubljana, Division of Medicine, Preventive Cardiology Unit, Ljubljana; (ii) Medical Faculty, University of Ljubljana, Ljubljana; (iii) University Medical Centre Ljubljana, University Children's Hospital, Dept. of Endocrinology, Diabetes and Metabolism, Ljubljana; (iv) University Medical Centre Ljubljana, University Children's Hospital, Ljubljana . SOUTH AFRICA: David Marais i (NLI), Frederick J. Raal ii (NLI), (i) University of Cape Town and National Health Laboratory Service; (ii) Division of Endocrinology & Metabolism, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. SPAIN: Pedro Mata i (NLI), Leopoldo Perez de Isla ii ; (i) Fundaci{\'o}n Hipercolesterolemia Familiar, Madrid; (ii) Hospital Cl{\'i}nico San Carlos, Madrid . SWEDEN: Lennart Nilsson (NLI); Dept. of Medical and Health Sciences, Link{\"o}ping University . SWITZERLAND: Andr{\'e} R. Miserez i,ii (NLI), Fran{\c c}ois J. Martin i,ii ; (i) diagene Research Institute, Swiss FH Center, Reinach; (ii) University of Basel . TAIWAN: Ta-Chen Su i (NLI), Ming-Ji Charng ii , Pei-Lung Chen iii ; (i) Dept. of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital; (ii) Faculty of Medicine, National Yang-Ming University; (iii) Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine . TURKEY: Meral Kayik{\c c}ioglu i (NLI), Lale Tokg{\"o}zoğlu; (i) Ege University Medical School Dept. of Cardiology, Izmir; (ii) Hacettepe Medical School Dept. of Cardiology, Ankara . UKRAINE: Olena Mitchenko (NLI); State Institution National Scientific Centre “The M.D. Strazhesko Institute of Cardiology National Academy of Medical Sciences of Ukraine”, Kiev . UNITED ARAB EMIRATES: Abdullah Shehab (NLI), Department of Internal Medicine, United Arab Emirates University-College of Medicine and Health Sciences, AlAin . UNITED KINGDOM: Handrean Soran (NLI), University Dept. of Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester . URUGUAY: Mario Stoll i (NLI), Nicol{\'a}s Dell{\textquoteright}Oca i , Graciela Fern{\'a}ndez i , Andr{\'e}s Ressia i , Ximena Reyes i , Mario Zelarayan i ; (i) Honorary Comission for Cardiovascular Health (CHSCV), Montevideo . UZBEKISTAN: Aleksander B. Shek i (NLI), Rano B. Alieva i , Shavkat U. Hoshimov i , Ravshanbek D. Kurbanov ii , Ulugbek I. Nizamov i ; ( i) CAD and Atherosclerosis Laboratory of Republican Specialized Center of Cardiology (RSCC), Ministry of Health of Republic Uzbekistan, Tashkent; (ii) Republican Specialized Center of Cardiology (RSCC), Ministry of Health of Republic Uzbekistan, Tashkent . VENEZUELA: Nelson Majano i (NLI), Marcos M. Lima-Mart{\'i}nez ii , (i) Hospital Militar de Caracas, Caracas; (ii) Ciudad Bolivar . VIETNAM: Thanh-Huong Truong i,ii (NLI), Mai-Ngoc Thi Nguyen ii , Doan-Loi Do i,ii , Ngoc-Thanh Kim i,ii , Hong-An Le iii , Thanh-Tung Le ii ; (i) Dept. of Cardiology, Hanoi Medical University, Hanoi; (ii) Vietnam National Heart Institute, Bach Mai Hospital, Hanoi; (iii) School of Medicine and Pharmacy, Vietnam National University, Hanoi .",

year = "2018",

month = oct,

day = "10",

doi = "10.1016/j.atherosclerosis.2018.08.051",

language = "English",

volume = "277",

pages = "234--255",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

AU - Уразгильдеева, Сорейя Асафовна

AU - Гуревич, Виктор Савельевич

N1 - Funding Information: The EAS FHSC project has received support from a Pfizer Independent Grant for Learning & Change 2014 (No: 16157823 ) and from investigator-initiated unrestricted research grants to the European Atherosclerosis Society from Amgen , MSD , and Sanofi-Aventis . Acknowledgments for/from specific initiatives and investigators are shown in the Supplemental Material . Appendix A Funding Information: National Lead Investigators for each country are identified as “NLI”. FHSC COORDINATING CENTRE : Asif Akram i , Josip Car i , Martina De Marco i , Kausik K. Ray i , Christophe A.T. Stevens i , Antonio J. Vallejo-Vaz i ; (i) Imperial College London, United Kingdom . ARGENTINA: Pablo Corral i (NLI), Laura Schreier ii ; (i) FASTA University, School of Medicine, Pharmacology Dept., Mar del Plata; (ii), University of Buenos Aires, Dept. of Clinical Biochemistry, Laboratory of Lipids and Atherosclerosis, INFIBIOC-UBA, Buenos Aires . AUSTRALIA: Gerald F. Watts i-iii (NLI), Jing Pang i ; (i) School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth; (ii) Lipid Disorders Clinic, Dept. of Cardiology, Royal Perth Hospital; (iii) FH Australasia Network (FHAN) . AUSTRIA: Christoph J. Binder i (NLI), Hans Dieplinger ii , Gabriele Hanauer-Mader iii ; (i) Dept. of Laboratory Medicine, Medical University of Vienna; (ii) Division of Genetic Epidemiology, Dept. of Medical Genetics, Clinical and Molecular Pharmacology, Innsbruck Medical University; (iii) Project Coordinator FH Registry/Austrian Atherosclerosis Society . BELGIUM: Olivier Descamps i (NLI), Johan Desutter ii , Michel Langlois iii , Ann Mertens iv , Ernst Rietzschel ii , Caroline Wallemacq v ; (i) Centres Hospitaliers Jolimont, Haine Saint-Paul; (ii) UZ Gent; (iii) AZ Brugge; (iv) UZ Leuven; (v) CHU Liège . BOSNIA AND HERZEGOVINA: Belma Pojskic i (NLI), Dzenana Isakovic i , Amra M. Dzankovic ii , Jasna Obralija iii , Lamija Pojskic i , Ibrahim Sisic i , Ena Stimjanin i , Vildana A. Torlak i ; (i) Cantonal Hospital Zenica; (ii) Private Internal Medicine Practice, Sarajevo; (iii) PI Health Center of Kakanj . BRAZIL: Raul D. Santos i,ii (NLI), Cinthia E. Jannes i , Jose E. Krieger i , Alexandre C. Pereira i ; (i) Heart Institute (InCor) University of Sao Paulo, Medical School Hospital; (ii) Hospital Israelita Albert Einstein, Sao Paulo . BULGARIA: Arman Postadzhiyan (NLI), Medical University of Sofia, President, Bulgarian Society of Cardiology . CANADA: Jacques Genest i (NLI), Isabelle Ruel i,ii ; (i) Research Institute of the McGill University Health Center, Montreal, Quebec; (ii) FH Canada Registry Coordinator . CHILE: Rodrigo Alonso i (NLI), Sylvia Asenjo ii , Ada Cuevas i ; (i) Clínica Las Condes, Santiago de Chile; (ii) Universidad de Concepción . CHINA: Jie Lin i (NLI), Lixin Jiang ii (NLI); (i) Beijing Institute of Heart, Lung and Blood Vessel Diseases; (ii) National Clinical Research Centre of Cardiovascular Diseases, Fuwai Hospital, National Centre for Cardiovascular Diseases, Beijing . CROATIA: Željko Reiner i (NLI), Ivan Pećin i ; (i) University of Zagreb, Zagreb School of Medicine, Dept. of Internal Medicine, Division of Metabolic Diseases, University Hospital Center Zagreb . CYPRUS: Phivos Symeonides i (NLI), George Miltiadous ii , Andrie G. Panayiotou ii ; (i) Hippocrateon Private Hospital, Nicosia; (ii) Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol . CZECH REPUBLIC: Tomas Freiberger i,ii (NLI), Michal Vrablik iii ; (i) Centre for Cardiovascular Surgery and Transplantation, Brno; (ii) Central European Institute of Technology, Masaryk University, Brno; (iii) General University Hospital and First Faculty of Medicine, Charles University, Prague . DENMARK: Børge G. Nordestgaard i,ii (NLI), Anne Tybjærg-Hansen i-iii (NLI), Marianne Benn ii,iii ; (i) Dept. Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital; (ii) Faculty of Health and Medical Sciences, University of Copenhagen; (iii) Dept. Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital . EGYPT: Ashraf Reda (NLI), Menofia University, President of the Egyptian Association of Vernacular Biology and Atherosclerosis (EAVA) . ESTONIA: Margus Viigimaa i (NLI), Silver Heinsar ii ; (i) Centre for Cardiovascular Medicine, North Estonia Medical Centre, Tallinn University of Technology; (ii) North Estonia Medical Centre, Tallinn University of Technology . FINLAND: Elisabeth Widén (NLI), Institute for Molecular Medicine Finland FIMM, University of Helsinki . FRANCE: Eric Bruckert i (NLI), S. Béliard ii ; (i) Dept. of Endocrinology, Institut E3M et IHU cardiométabolique, Hôpital Pitié Salpêtrière, Paris; (ii) Dept. of Endocrinology, APHM, Aix Marseille Univ, INSERM, INRA, C2VN, Marseille . GERMANY: Ulrich Laufs i (NLI), Winfried März ii-v (NLI), Heribert Schunkert vi (NLI), Ioanna Gouni-Berthold vii , Wibke Hengstenberg viii , Ulrich Julius ix , Ursula Kassner x , Gerald Klose xi , Christel König xii , Wolfgang König viii , Britta Otte xiii , Klaus Parhofer xiv , Ulrike Schatz ix , Nina Schmidt iv , Elisabeth Steinhagen-Thiessen x , Anja Vogt xiv ; (i) Klinik und Poliklinikfür Kardiologie, Universitäts klinikum Leipzig; (ii) Medizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim; (iii) Synlab Akademie, Synlab Holding Deutschland GmbH, Mannheim und Augsburg; (iv) D-A-CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V., Hamburg; (v) KlinischesInstitutfür Medizinische und Chemische Labordiagnostik, Medizinische Universität Graz, Graz, Austria; (vi) Deutsches Herzzentrum München, Technische Universität München, Deutsches Zentrumfür Herz-und Kreislauferkrankungen (DZHK), Munich Heart Alliance; (vii) Center for Endocrinology, Diabetes, and Preventive Medicine, University of Cologne; (viii) Deutsches Herzzentrum, Munich; (ix) Dept. of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden; (x) Center for Internal Medicine with Gastroenterology and Nephrology, Lipid Clinic, Charité Berlin; (xi) Joint Practice for Internal Medicine, Gastroenterology and Cardiology Beckenbauer & Maierhof, Bremen; (xii) Clinic of Internal Medicine, Lipid Clinic, Klinikum Links der Weser, Bremen; (xiii) Medical Clinic D, Lipid Clinic, University Hospital Münster; (xiv) Medical Clinic and Policlinic IV, Ludwig-Maximilian University, Munich . GREECE: Evangelos Liberopoulos i (NLI), Alexandros D. Tselepis ii (NLI), Christina Antza iii , Vasilios Athyros iii , Eleni Bilianou iv , Amalia Boufidou v , George Chrousos vi , Moses Elisaf i , Anastasia Garoufi vii , Niki Katsiki viii , Genovefa Kolovou ix , Vasilios Kotsis iii , Loukianos Rallidis x , Christos Rizos i , Emmanouel Skalidis xi , Ioannis Skoumas xii , Kostantinos Tziomalos xiii ; (i) Faculty of Medicine, University of Ioannina; (ii) Atherothrombosis Research Centre, University of Ioannina; (iii) Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, Papageorgiou Hospital, Thessaloniki; (iv) Dept. of Cardiology, Tzaneio Hospital, Athens; (v) Dept. of Cardiology, AHEPA Hospital, Thessaloniki; (vi) First Dept. of Pediatrics, National and Kapodistrian University of Athens Medical School, St. Sophia Children Hospital, Athens; (vii) Second Dept. of Pediatrics, Medical School, National & Kapodistrian University of Athens, “P & A Kyriakou” Children's Hospital; (viii) Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, Hippokrateion Hospital, Thessaloniki; (ix) Dept. of Cardiology, Onassis Cardiac Surgery Centre, Athens; (x) Dept. of Cardiology, University of Athens Medical School, Attiko University Hospital, Athens; (xi) Dept. of Cardiology, University Hospital of Herakleion; (xii) Dept. of Cardiology, Hippokrateion Hospital, Athens; (xiii) First Propedeutic Dept. of Internal Medicine, Aristotle University of Thessaloniki Medical School, AHEPA Hospital, Thessaloniki . HONG KONG: Brian Tomlinson (NLI), Dept. of Medicine and Therapeutics, The Chinese University of Hong Kong . HUNGARY: György Paragh (NLI), Dept. of Internal Medicine, University of Debrecen Faculty of Medicine, Debrecen . INDIA: Tester F. Ashavaid i (NLI), J.P.S. Shawney ii ; (i) P. D Hinduja National Hospital and Medical Research Centre, Mumbai; (ii) Sir Ganga Ram Hospital, Delhi . IRAN: Amirhossein Sahebkar i-iii (NLI), Mohammad R. Abbaszadegan iv , Majid Aminzadeh v , Sousan Hosseini iv , Moein Mobini vi , Rahim Vakili iv,vii , Hossein Zaeri viii ; (i) Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences; (ii) Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences; (iii) School of Pharmacy, Mashhad University of Medical Sciences; (iv) Medical Genetics Research Center, Mashhad University of Medical Sciences; (v) Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz; (vi) School of Medicine, Mashhad University of Medical Sciences; (vii) Dept. of Paediatric Endocrinology and Metabolism, Faculty of Medicine, Mashhad University of Medical Sciences; (viii) Neonatal and Children Health Research Centre, Golestan University of Medical Sciences, Gorgan . IRAQ: Mutaz Al-khnifsawi (NLI), Al-Qadisiyah University, Faculty of Medicine, Dept. of Internal Medicine, Diwaniya City . IRELAND: Vincent Maher i (NLI), Ruth Agar i , Gerard Boran ii , Nial Colwell iii , Vivion Crowley iv , Maeve Durkin v , Damian Griffin vi , Michael Kelly ii , Ana Rakovac-Tisdall iv ; (i) Advanced Lipid Management and Research (ALMAR) Centre, Dublin; (ii) Tallaght University Hospital, Dublin; (iii) South Tipperary General Hospital; (iv) St James Hospital, Dublin; (v) Bon Secours Hospital Cork; (vi) University Hospital Galway . ISRAEL: Ronen Durst i (NLI), Rafael Bitzur ii , Hofit Cohen ii , Osnat Eliav iii , Avishay Ellis iv , Dov Gavish v , Dror Harats ii , Yaacov Henkin vi , Hila Knobler vii , Leah Leavit iii , Eran Leitersdorf iii , Ardon Rubinstein viii , Daniel Schurr iii , Shoshi Shpitzen iii , Auryan Szalat iii ; (i) Cardiology Dept. and Center for Treatment and Prevention of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem; (ii) Bert W. Strassburger Lipid Center, the Chaim Sheba Medical Center, Tel Hashomer; (iii) Center for Research Prevention and Treatment of Atherosclerosis, Dept. of Medicine, Hadassah Hebrew University Medical Center, Jerusalem; (iv) Internal Medicine, Rabin Medical Center, Petah Tikva; (v) Dept. of Medicine, Wolfson Medical Center, Holon; (vi) Dept. of Cardiology, Soroka University Medical Center, Beer-Sheva; (vii) Diabetes and Metabolic Disease Unit, Kaplan Medical Center, Rehovot; (viii) Dept. of Metabolic Clinic, Tel Aviv Medical Center, Tel Aviv . ITALY: Alberico L. Catapano i,ii (NLI), Marcello Arca iii , Maurizio Averna iv , Stefano Bertolini v , Sebastiano Calandra vi , Patrizia Tarugi vii ; (i) Dept. of Pharmacological and Biomolecular Sciences, University of Milan, Milan; (ii) IRCCS MultiMedica, Sesto S. Giovanni, Milan; (iii) Dept. of Internal Medicine and Medical Specialties, Sapienza University, Rome; (iv) Biomedical Dept. of Internal Medicine and Specialistics (DIBIMIS), University of Palermo; (v) Dept. of Internal Medicine, University of Genoa; (vi) Dept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; (vii) Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena . JAPAN: Mariko Harada-Shiba i (NLI), Shizuya Yamashita ii (NLI); (i) National Cerebral and Cardiovascular Centre Research Institute, Suita, Osaka; (ii) Rinku General Medical Center and Osaka University Graduate School of Medicine, Osaka . KUWAIT: Ahmad Al-Sarraf (NLI), Laboratory Dept., Kuwait Cancer Control Center, Kuwait City . KYRGYZSTAN: Erkin Mirrakhimov (NLI), Kyrgyz State Medical Academy, National Centre of Cardiology and Internal Diseases, Biskek . LATVIA: Gustavs Latkovskis i (NLI), Andrejs Erglis i , Dainus Gilis ii , Georgijs Nesterovics iii , Vita Saripo iv , Arta Upena-Roze ii ; (i) Research Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga; (ii) University of Latvia, Pauls Stradins Clinical University Hospital, Riga; (iii) Faculty of Medicine, University of Latvia, Riga; (iv) Faculty of Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga . LEBANON: Marianne Abifadel i (NLI), Sandy Elbitar i , Sélim Jambart ii , Petra El Khoury i ; (i) Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University, Beirut; (ii) Saint Joseph University of Beirut Faculty of Medicine and Hôtel Dieu Hospital, Beirut . LITHUANIA: Zaneta Petrulioniene i-iii (NLI), Urte Gargalskaite i,iii , Sandra Kutkiene i-iii ; (i) Vilnius University, Faculty of Medicine; (ii) Vilnius University, Faculty of Medicine, Clinic of Cardiac and Vascular Diseases; (iii) Vilnius University hospital Santaros Klinikos . MALAYSIA: Hapizah M. Nawawi i (NLI), Alyaa Al-Khateeb, Chua Y. An, Zaliha Ismail, Sazzli Kasim, Khairul S. Ibrahim, Ahmad B.M. Radzi, Noor A. Kasim, Noor S.M. Nor, Anis S. Ramli, Suraya A. Razak, Suhaila Muid, Azhari Rosman, Abd R. Sanusi, Aimi Z. Razman, Sukma A. Nazli, Teh L. Kek; (i) Institute of Pathology, Laboratory and Forensic Medicine (I-PPerForM), (ii) Faculty of Medicine Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, Selangor, (iii) National Heart Institute (IJN), Kuala Lumpur, (iv) The Malaysian Atherosclerosis Society (MSA) . MALTA: Myra Tilney i,ii (NLI), Conrad Azzopardi i,ii ; (i) Dept. of Medicine, Faculty of Medicine and Surgery, University of Malta; (ii) Lipid Clinic, Mater Dei Hospital . MEXICO: Carlos A. Aguilar Salinas i (NLI), N. Alejandra Vázquez-Cárdenas ii (NLI), Gabriela Galán i , MT Magaña-Torres iii , Alexandro Martagon i , Roopa Mehta i ; (i) Instituto Nacional de Ciencias Médicas y Nutrición, México City; (ii) Facultad de Medicina, Universidad Autónoma de Guadalajara, Guadalajara, México; (iii) Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social . NETHERLANDS: G. Kees Hovingh i (NLI), John J.P. Kastelein i (NLI), M.E. Wittekoek ii ; (i) Dept. of Vascular Medicine, Academic Medical Center, Amsterdam; (ii) Director, LEEFH (Landelijk Expertisecentrum Erfelijksheidsonderzoek Familiaire Hart - En Vaatziekten) . NIGERIA: Wilson E. Sadoh i (NLI), Alphonsus R. Isara ii , Darlington E. Obaseki iii , Oluwatoyin A. Ohenhen iv ; (i) Cardiology unit, Dept. of Child Health, University of Benin Teaching Hospital, Benin City, Edo State; (ii) Dept. of Community Medicine, University of Benin Teaching Hospital, Benin City; (iii) Dept. of Pathology, University of Benin Teaching Hospital, Benin City; (iv) Dept. of Medicine, University of Benin Teaching Hospital, Benin City . NORWAY: Martin P. Bogsrud i,ii (NLI), Kirsten B. Holven ii,iii ; (i) Unit for Cardiac and Cardiovascular Genetics, Dept. of Medical Genetics, Oslo University Hospital; (ii) Norwegian National Advisory Unit on Familial Hypercholesterolemia, Dept. of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital; (iii) Dept. of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo . OMAN: Khalid Al-Rasadi (NLI), Sultan Qaboos University Hospital, Muscat . PHILIPPINES: Lourdes E. Santos (NLI); Cardinal Santos Medical Centre, University of the Philippines – Philippine General Hospital . POLAND: Maciej Banach i (NLI), Krzysztof Chlebus ii,iii , Marcin Gruchała ii,iii , Marlena Baranowska iii , Justyna Borowiec-Wolny iii , Natasza Gilis-Malinowska iii , Aleksandra Michalska-Grzonkowska iii , Marcin Pajkowski iii , Aleksandra Parczewska iii , Marzena Romanowska-Kocejko iii , Aneta Stróżyk iii , Marta Żarczyńska-Buchowiecka ii,iv , Mariola Kleinschmidt v ; (i) Dept. of Hypertension, Medical University of Lodz; (ii) 1st Dept. of Cardiology, Medical University of Gdansk; (iii) Clinical Centre of Cardiology, University Clinical Centre in Gdańsk; (iv) Dept. of Heart Disease Diagnosis, University Clinical Centre in Gdańsk; (v) Dept. of Sales and Purchase of Medical Services, University Clinical Centre in Gdańsk. PORTUGAL: Mafalda Bourbon i,ii (NLI), Ana C. Alves i,ii , Ana M. Medeiros i,ii ; (i) Unidade I&D, Grupo de Investigação Cardiovascular, Dept. de Promoção da Saúde e Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa; (ii) University of Lisboa, Faculty of Sciences, BioISI – Biosystems & Integrative Sciences Institute, Campo Grande, Lisboa . QATAR: Fahad A. AlKindi i (NLI), (i) Hamad Medical Corporation, Heart Hospital, Doha. ROMANIA: Dan Gaita (NLI); Universitatea de Medicina si Farmacie Victor Babes din Timisoara . RUSSIA: Marat Ezhov i (NLI), Andrey V. Susekov ii (NLI), Alexandra Ershova iii , Victoria Korneva iv , Tatiana Kuznetsova iv , Pavel Malyshev v , Alexey Meshkov iii , Tatiana Rozhkova v ; (i) National Cardiology Research Center of Ministry of Health of the Russian Federation; (ii) Faculty of Clinical Pharmacology and Therapeutics, Academy for Postgraduate Medical Education and Central Clinical Hospital, Academy of Medical Science, Moscow; (iii) Federal State Institution "National Research Center for Preventive Medicine" of the Ministry of Healthcare of the Russian Federation, Moscow; (iv) Petrozavodsk State University, Petrazavodsk; (v) National Research Center for Cardiology, Moscow . SAUDI ARABIA: Fahad Alnouri (NLI), Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre Riyadh, Riyadh . SERBIA: Katarina Lalic i (NLI), Natasa Rajkovic i , Ljiljana Popovic i , Sandra S. Lukac i , Ljubica Stosic i , Iva Rasulic i , Nebojsa M. Lalic i ; (i) Faculty of Medicine, University of Belgrade; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade . SINGAPORE: Tavintharan Subramaniam i-iii (NLI), Carolyn S.P. Lam iv (NLI), Terrance S.J. Chua v , Sharon P.L. Ting iii ; (i) Diabetes Centre, Admiralty Medical Centre; (ii) Division of Endocrinology, Khoo Teck Puat Hospital; (iii) Clinical Research Unit, Khoo Teck Puat Hospital; (iv) National Heart Centre Singapore, Duke-NUS Medical School; (v) National Heart Centre Singapore . SLOVAKIA: Branislav Vohnout i,ii (NLI), Katarina Raslova ii ; (i) Institute of Nutrition, FOZOS, Slovak Medical University, Bratislava; (ii) Coordination Center for Familial Hyperlipoproteinemias, Slovak Medical University, Bratislava . SLOVENIA: Zlatko Fras i,ii (NLI), Urh Groselj iii (NLI), Tadej Battelino iv , Matija Cevc i , Borut Jug i , Jernej Kovac iv , Katarina T. Podkrajsek iv , Ursa Sustar iv , Katja J. Trontelj i ; (i) University Medical Centre Ljubljana, Division of Medicine, Preventive Cardiology Unit, Ljubljana; (ii) Medical Faculty, University of Ljubljana, Ljubljana; (iii) University Medical Centre Ljubljana, University Children's Hospital, Dept. of Endocrinology, Diabetes and Metabolism, Ljubljana; (iv) University Medical Centre Ljubljana, University Children's Hospital, Ljubljana . SOUTH AFRICA: David Marais i (NLI), Frederick J. Raal ii (NLI), (i) University of Cape Town and National Health Laboratory Service; (ii) Division of Endocrinology & Metabolism, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg. SPAIN: Pedro Mata i (NLI), Leopoldo Perez de Isla ii ; (i) Fundación Hipercolesterolemia Familiar, Madrid; (ii) Hospital Clínico San Carlos, Madrid . SWEDEN: Lennart Nilsson (NLI); Dept. of Medical and Health Sciences, Linköping University . SWITZERLAND: André R. Miserez i,ii (NLI), François J. Martin i,ii ; (i) diagene Research Institute, Swiss FH Center, Reinach; (ii) University of Basel . TAIWAN: Ta-Chen Su i (NLI), Ming-Ji Charng ii , Pei-Lung Chen iii ; (i) Dept. of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital; (ii) Faculty of Medicine, National Yang-Ming University; (iii) Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine . TURKEY: Meral Kayikçioglu i (NLI), Lale Tokgözoğlu; (i) Ege University Medical School Dept. of Cardiology, Izmir; (ii) Hacettepe Medical School Dept. of Cardiology, Ankara . UKRAINE: Olena Mitchenko (NLI); State Institution National Scientific Centre “The M.D. Strazhesko Institute of Cardiology National Academy of Medical Sciences of Ukraine”, Kiev . UNITED ARAB EMIRATES: Abdullah Shehab (NLI), Department of Internal Medicine, United Arab Emirates University-College of Medicine and Health Sciences, AlAin . UNITED KINGDOM: Handrean Soran (NLI), University Dept. of Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester . URUGUAY: Mario Stoll i (NLI), Nicolás Dell’Oca i , Graciela Fernández i , Andrés Ressia i , Ximena Reyes i , Mario Zelarayan i ; (i) Honorary Comission for Cardiovascular Health (CHSCV), Montevideo . UZBEKISTAN: Aleksander B. Shek i (NLI), Rano B. Alieva i , Shavkat U. Hoshimov i , Ravshanbek D. Kurbanov ii , Ulugbek I. Nizamov i ; ( i) CAD and Atherosclerosis Laboratory of Republican Specialized Center of Cardiology (RSCC), Ministry of Health of Republic Uzbekistan, Tashkent; (ii) Republican Specialized Center of Cardiology (RSCC), Ministry of Health of Republic Uzbekistan, Tashkent . VENEZUELA: Nelson Majano i (NLI), Marcos M. Lima-Martínez ii , (i) Hospital Militar de Caracas, Caracas; (ii) Ciudad Bolivar . VIETNAM: Thanh-Huong Truong i,ii (NLI), Mai-Ngoc Thi Nguyen ii , Doan-Loi Do i,ii , Ngoc-Thanh Kim i,ii , Hong-An Le iii , Thanh-Tung Le ii ; (i) Dept. of Cardiology, Hanoi Medical University, Hanoi; (ii) Vietnam National Heart Institute, Bach Mai Hospital, Hanoi; (iii) School of Medicine and Pharmacy, Vietnam National University, Hanoi .

PY - 2018/10/10

Y1 - 2018/10/10

N2 - Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

AB - Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

KW - FHSC

KW - Familial hypercholesterolaemia

KW - Primary dyslipidaemia

UR - http://www.scopus.com/inward/record.url?scp=85053666909&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2018.08.051

DO - 10.1016/j.atherosclerosis.2018.08.051

M3 - Article

VL - 277

SP - 234

EP - 255

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -

ID: 37207549